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Abstract
Introduction: Tumor cell proliferation in breast cancer is strongly prognostic and may also predict response to
chemotherapy. However, there is no consensus on counting areas or cut-off values for patient stratification. Our aim was to
assess the matched level of proliferation by Ki67 when using different tissue categories (whole sections, WS; core needle
biopsies, CNB; tissue microarrays, TMA), and the corresponding prognostic value.
Methods: We examined a retrospective, population-based series of breast cancer (n= 534) from the Norwegian Breast
Cancer Screening Program. The percentage of Ki67 positive nuclei was evaluated by visual counting on WS (n= 534), CNB
(n= 154) and TMA (n= 459).
Results: The median percentage of Ki67 expression was 18% on WS (hot-spot areas), 13% on CNB, and 7% on TMA, and this
difference was statistically significant in paired cases. Increased Ki67 expression by all evaluation methods was associated
with aggressive tumor features (large tumor diameter, high histologic grade, ER negativity) and reduced patient survival.
Conclusion: There is a significant difference in tumor cell proliferation by Ki67 across different sample categories. Ki67 is
prognostic over a wide range of cut-off points and for different sample types, although Ki67 results derived from TMA
sections are lower compared with those obtained using specimens from a clinical setting. Our findings indicate that
specimen specific cut-off values should be applied for practical use.
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Introduction
Breast cancer is a heterogeneous disease. During the last
decade, gene expression studies have identified distinct molecular
subtypes, such as Luminal A, Luminal B, HER2-enriched, basal-
like and normal breast-like, and these have markedly different
behavior and prognosis [1,2]. Subsequent studies have introduced
immunohistochemical surrogate markers for molecular classifica-
tion, with a proposed Ki67 cut-point of 14% to separate Luminal
A from Luminal B tumors [3,4]. Furthermore, the treatment effect
of adding docetaxel to highly proliferative, luminal tumors has
been demonstrated [5,6].
In 2011, the St Gallen International Expert Consensus included
a Ki67 cut-off point of 14% in their recommendations for adjuvant
therapy [7]. However, there is currently no agreement on
specimen selection, technical protocols, evaluation methods or
cut-off values [8,9], and the criteria for sub-classification of breast
carcinomas by Ki67 has yet to be established. This area is
controversial, and in the report from St Gallen 2013 recently
published, the cut-off value has been changed [10].
On this background, we aimed to study the levels of tumor cell
proliferation based on Ki67 expression according to specimen type
such as whole sections (WS), core needle biopsies (CNB) and tissue
microarrays (TMA) from a population-based series of breast
cancers, and to study and compare the prognostic value of Ki67 in
relation both to specimen type and molecular subgroups of breast
cancer.
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Materials and Methods
Patient series
This study was approved by the Western Regional Committee
for Medical and Health Research Ethics, REC West (REK 2012/
1704). We identified all women (50–69 years) who resided in
Hordaland County, Norway, when diagnosed with primary
invasive breast cancer as part of the population-based Norwegian
Breast Cancer Screening Program during 1996-2003. Hordaland
County has approximately 500,000 inhabitants, this represents
about 10% of the total population of Norway.
Patients with distant metastatic disease at time of diagnosis
(stage IV) were not included, leaving 555 potential cases. Written
informed consent was not obtained from the patients, but in
accordance with national ethics guidelines and procedures for such
retrospective studies, all participants were contacted with written
information on the study and asked to respond if they objected. In
total, 9 patients (1.6%) did not approve participation. 12 cases had
technical inadequate material for proliferation assessment (Ki67),
leaving 534 cases for further studies. Patient records and
information were anonymized and de-identified prior to analysis.
The patients included had a median age of 60 years at diagnosis
(factual range 49–72 years).
The patients received treatment according to standard national
protocols in a single institution. Follow-up information was given
by the Norwegian Cause of Death Registry, and can be considered
accurate and complete. Last date of follow-up was December 31,
2011. Outcome data include survival status, survival time and
cause of death. During the follow-up period, 79 patients (15%)
died from breast carcinoma, and 62 (12%) died from other causes.
The median survival of the censored patients was 12 years, and the
median follow-up was 13 years calculated by the reverse Kaplan-
Meier method. The 5-year breast cancer specific mortality was 9%
(49/534).
Clinico-pathological variables
Patient’s clinical history and tumor characteristics including age
at diagnosis, largest tumor diameter, histologic type, histologic
grade, lymph node status and hormonal receptor status were
obtained from the clinical records and routine histopathology
reports. Histologic type was assessed according to WHO criteria,
whereas histologic grade was evaluated using the Nottingham
modification [11] by five experienced breast pathologists (JE, JA,
IMS, KC, LAA). Tumor size was assessed histologically (61%) and
by macroscopic examination (29%). However, if pathologic tumor
size was not available (as in patients with locally advanced or
multifocal disease), the radiologic size estimate was included
(10%). For immunohistochemical studies on whole sections, HE
slides were re-examined, and representative slides (1–2 blocks)
displaying both the peripheral and central parts of the tumor, as
well as the most cellular and high-grade areas, were selected for
further analyses. The corresponding FFPE block was also used for
TMA construction.
Patient characteristics
Radical mastectomy was performed in 285 cases (53%), and
breast conserving surgery in 245 cases (46%); four patients were
represented with core needle biopsy only (three cases of locally
advanced disease and one patient with surgery abroad). Adjuvant
therapy was decided according to tumor size, histologic grade,
hormone receptor status and nodal status. Treatment protocols
showed slight modifications during the period. Chemotherapy was
offered to patients below 55 years with stage I disease who had
histologic grade 2 and 3 tumors, and to patients under 55 years
with stage II disease. From 1998, chemotherapy was also
recommended for patients between 55–65 years with stage I or
II disease combined with hormone receptor negativity. 33 patients
(6%) were treated with neo-adjuvant chemotherapy due to locally
advanced disease.
Adjuvant radiation therapy was recommended for patients who
received breast conserving surgery, had primary surgery without
free resection margins, stage II disease with axillary metastasis, as
well as stage III disease.
Specimen characteristics
The tumor samples were fixed in 4% buffered formaldehyde
before processing and embedding in paraffin. Storage time of the
archival formalin-fixed, paraffin embedded tissue samples (blocks)
was up to 17 years. Five mm sections were cut by one person using
the same microtome and mounted onto poly-lysine coated glass
slides. Slides were stored for no longer than two weeks at 4uC until
staining for Ki67 was performed.
Tissue microarray (TMA). H&E stained slides were used
for tumor verification. Briefly, 1.0 mm cores in triplicate were
punched and mounted into a recipient paraffin block using a semi-
automated precision instrument (Minicore 3, Tissue Arrayer,
Alphelys, France). Care was taken to select areas with high tumor
purity and to include the periphery and areas of highest histologic
grade. 190 cases had previously been processed [12,13]; from
these cases three tissue cores with a diameter of 0.6 mm were
obtained by a different instrument (Beecher Instruments, Silver
Spring, MD, USA).
Among the 534 cases with TMA available, 22 cases had tissue
cores devoid of invasive tumor, 21 cases had complete core loss
and 32 cases showed fewer than 100 tumor cells on arrayed spots,
leaving 459 cases (86%) available for proliferation assessment.
Preoperative core needle biopsies (CNB). 182 patients
had undergone both preoperative core needle biopsy and
subsequent primary surgical excision for breast carcinoma. Among
these, 25 cases were excluded due to non-representative or
inadequate material remaining for biomarker assessment. Three
cases had previously been excluded due to lack of informed
consent. In total, 310 cases received preoperative cytology only,
and the remaining cases had either frozen sections, incisional or
excisional biopsies performed; this practice was according to
national guidelines at the time. The number of core biopsies taken
ranged from 1 to 4 (mean= 2.4, median = 2). 92% of the cases had
more than 1 core biopsy available.
Ki67 immunohistochemistry
Immunohistochemistry was performed on 5 mm slides of
formalin-fixed and paraffin-embedded archival tumor tissue. The
sections were de-waxed with xylene/ethanol before target retrieval
in a pressure cooker (Decloaking Chamber Plus, Biocare Medical).
Staining procedures were performed on a DAKO autostainer
using the K4061/Envision Dual Link System (rabbit+mouse).
Sections were incubated for 30 minutes at room temperature with
a monoclonal rabbit antibody (M 7240, clone MIB-1, DAKO) at a
1:100 dilution. Finally, diaminobenzidine (DAB) as chromogen for
10 minutes was followed by haematoxylin as counterstain for
3 minutes. Sections from tonsils were used as positive controls;
negative controls were obtained by replacing the primary antibody
with Tris-buffered saline. Controls were included in each staining
run.
Evaluation of staining
Hormone receptors. Results for estrogen and progesterone
receptors were obtained from the routine pathology reports.
Proliferation by Ki67 Expression in Breast Cancer
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Tumors were considered ER or PR positive if $10% of tumor
nuclei stained positive, according to national guidelines during the
period.
HER2. The established scoring system for DAKO Herceptest
was used. HER2 SISH was performed on IHC 2+ cases (Ventana
INFORM HER2 DNA probe staining). The 2+ cases were
considered HER2 positive if the HER2/Chr17 ratio by SISH was
equal to or greater than 2.0.
Ki67 scoring. All slides were examined and scored by one
pathologist (GK), blinded to patient characteristics and outcome.
The slides were evaluated using light microscopy (Leica DMLB)
with an eye-piece graticule for counting at x630 magnification,
roughly following the approach used by Weidner et al. [14]. Care
was taken to avoid areas of intense inflammation, fibrosis, necrosis,
low cellularity or poor fixation. The slides were scanned at low
magnification (x100) to identify and encircle the hot-spot (HS); this
was defined as the area containing the highest density of Ki67-
labelled tumor cells by visual impression. The hot-spot was usually
situated at the periphery of the carcinoma. Further, the cold-spot
(CS), the area with the lowest density of Ki67 positive tumor
nuclei, was identified. Overall, 23% of all cases (WS) showed
clearly heterogeneous proliferation. In these cases, 500 tumor cells
in consecutive HPFs were counted in both hot and cold spots. For
tumors with homogenous proliferation, or small areas of invasive
tumor, 500 tumor cells at the peripheral part of the tumor were
assessed, and a single figure for Ki67 expression was recorded.
Only stained tumor cells crossing horizontal grid lines were
counted. Any nuclear staining regardless of intensity was
considered positive.
We did not find any correlation between Ki67 expression and
years of storage of the tissue blocks (data not shown). Further, we
found no difference in median Ki67 expression when comparing
patients with 1–2 core biopsies (CNB) available versus 3–4 core
biopsies (data not shown).
In a subset of 50 cases, the slides were evaluated at a different
magnification (x400), with excellent correlation between the
methods (Spearman’s correlation coefficient (r) 0.96, kappa-value
0.79, P,0.001 for both tests).
Observer agreement for Ki67 counts. Intra-observer
variability was evaluated by randomly rechecking 50 cases (WS)
after a period of 6 months, with excellent correlation between the
2 counts (Spearman’s r 0.99, kappa-value 0.88). Moreover, a
separate researcher (SA) assessed 50 cases across all sample
categories showing good inter-observer agreement: WS specimens:
Spearman’s r 0.95; kappa-value 0.71; CNB specimens: Spear-
man’s r 0.93; kappa-value 0.80; TMA specimens: Spearman’s r
0.88; kappa-value 0.74 (P,0.001 for each analysis).
For assessment of Ki67 on CNB, 500 tumor cells were counted
by choosing the most proliferative region if possible. For
assessment of Ki67 on TMA, all available cores were assessed,
and the core with the highest Ki67 score was recorded. TMA
samples with fewer than 100 tumor cells were considered not
interpretable.
Furthermore, an ‘‘average’’ tumor cell proliferation was
estimated as a mean of Ki67-HS and Ki67-CS in cases of
heterogeneity. In a subgroup of 25 cases, the overall average score
was also directly counted on the slides in addition to the estimated
average. This was obtained by counting 200 cells in each of three
representative tumor areas (hot-spot, intermediate area and cold-
spot). There was a strong and positive correlation between the
average score obtained by counting and the estimated mean
(Spearman’s r 0.86, P,0.001, kappa-value 0.62, P=0.001).
Definition of molecular classes of breast cancer
Molecular classes were defined as Luminal A (ER positive and/
or PR positive, Ki67,14%), Luminal B (LuminalB-HER2
negative: ER positive and/or PR positive, Ki67$14%; Lumi-
nalB-HER2 positive: HR positive and HER2 positive regardless of
Ki67), HER2 enriched (ER and PR negative, HER2 positive), and
triple negative (ER negative, PR negative, HER2 negative) based
on published criteria [7].
Statistical methods
Analyses were performed using the SPSS statistical package,
version 18.0 (SPSS Inc., Chicago, IL). Statistical significance was
assessed at the two-sided 5% level. Non-parametric correlations
were tested by the Spearman’s rank coefficient. Bland and Altman
analysis and Wilcoxon signed rank tests were used to compare
related samples. Continuous variables not following the normal
distribution were compared between two or more groups using the
Mann-Whitney U or Kruskal-Wallis H-test. Continuous variables
were categorized based on quartile limits, also considering the
frequency distribution plot for each marker, as well as the number
of events in subgroups. The Cohen’s kappa measure was used to
assess the agreement of two categorical scores.
For survival analyses, the end-point of interest was breast cancer
specific survival (BCSS), defined as the time in months from the
date of diagnosis to the date of death from breast cancer. Patients
with missing data were excluded from analyses. Univariate
survival analyses were performed using the product-limit proce-
dure (Kaplan-Meier method), and differences between categories
were estimated by the log-rank test, with date of diagnosis as the
starting point. Patients who died from other causes were censored
at the date of death. Multivariate survival analyses were conducted
using Cox9 proportional hazards methods. Multivariate analyses
adjusted for standard prognostic factors including tumor size,
histologic grade, nodal status and age. Covariates were examined
by log-log plot and by adding interaction terms to determine their
ability to be incorporated in multivariate models. For continuous
variables, the proportional hazard assumptions were also assessed
by studying the graphs of Schoenfelds residuals.
Results
Clinico-pathologic characteristics of the patients
In the current study, median tumor size was 15 mm (range 3–
110 mm). Table 1 gives an overview of clinico-pathological
features of the complete series. See also table S1 in File S1 for a
summary of clinico-pathologic characteristics in relation to
molecular subclasses.
Among patients that underwent axillary node dissection, the
median number of lymph nodes sampled was 11 (range 1–33).
Ki67 counts in relation to different specimen types
The following results are based upon hot-spot counts, unless
otherwise is stated. The median percentages of Ki67 expression
according to specimen types for both the complete series and paired
cases are listed in Table 2, see also Figure S1-A. Ki67 counts were
significantly higher in WS as compared to CNB (n= 154, Wilcoxon
signed rank test, P=0.001), with a median absolute difference of
2.4% (range 244% to 42%), see Figure S1-B.
Ki67 counts were significantly higher in WS as compared to
TMA (n= 459, Wilcoxon signed rank test, P,0.001), with a
median absolute difference of 10% (range 26 to 76%). Further-
more, an increase in variability of the differences with increasing
proliferation was shown (See Figure S1-C).
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In 137 cases with matched WS, CNB and TMA samples, the
median percentages of Ki67 expression were significantly different
with 17% (WS), 13% (CNB) and 6% (TMA), Wilcoxon signed
rank test, P,0.001 for each analysis. Still, The Ki67 values
obtained on WS were significantly correlated with both CNB
(Spearman’s r 0.56, P=0.001) and TMA (Spearman’s r 0.81, P,
0.001). Further, Ki67 counts on CNB were significantly correlated
with TMA (Spearman’s r 0.49, P,0.001) (See Figure S2).
Using the 14% Ki67 threshold on the entire series (n = 534),
based on WS specimens, 61% of tumors were classified as having
high proliferation. In the CNB series (n = 154), 48% showed high
Ki67 expression, as compared to 25% of the cases when using
TMA specimens (n = 459), as illustrated in Figure S3.
Table 1. Clinico-pathologic characteristics.
Characteristics Complete series
N (%)
Tumor diameter
#2 cm 405 75.8
.2 cm 129 24.2
Histologic grade
1 218 40.8
2 226 42.3
3 90 16.9
Nodal status
Negative 387 72.5
Positive 142 26.6
Missing 5 0.9
Histologic type
Ductal 447 83.7
Lobular 55 10.3
Tubular 8 1.5
Mucinous 16 3.0
Medullary 4 0.7
Unclassified 4 0.7
ER
Positive 451 84.5
Negative 83 15.5
PR
Positive 377 70.6
Negative 157 29.4
HER2
Negative 463 86.7
Positive 71 13.3
doi:10.1371/journal.pone.0112121.t001
Table 2. Ki67 counts according to tissue categories.
Complete series N Median Range Mean
Ki67-WS 534 18 1–94 24
Ki67-CNB 154 13 0.4–89 17
Ki67-TMA 459 7 0.2–83 12
Paired cases
Ki67-WS 137 17 0.8–90 21
Ki67-CNB 137 13 0.4–89 18
Ki67-TMA 137 6 0.2–71 10
WS, whole sections; CNB, core needle biopsies; TMA, tissue micro arrays.
doi:10.1371/journal.pone.0112121.t002
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Associations between Ki67 and clinico-pathological
features
High Ki67 expression by all 3 classes of specimens was
significantly associated with high histologic grade and hormone
receptor negativity (Table 3). Furthermore, elevated Ki67 expres-
sion on WS and TMA was associated with large tumor size, lymph
node metastasis, and HER2 positivity. No associations were found
between high Ki67 and age or tumor type. For cold-spot counts on
full sections, the associations between Ki67 and tumor size and
HER2 status were not significant (See Table S2 in File S1).
Tumor cell proliferation in different molecular subgroups
Based on WS (complete series), the median expression of Ki67
in the Luminal subclass (including Luminal-HER2+) was 17%
(Luminal A subclass 7%, Luminal B subclass 25%). In the HER2+
subclass (HR-, HER2+), the median expression of Ki67 was 35%
whereas the triple negative subgroup demonstrated the highest
Ki67 median of 62% (Kruskal-Wallis test, P,0.001, Figure 1).
Assessment on CNB and TMA revealed the same pattern with
highest proliferation shown for the triple negative group followed
by the HER2+ subgroup. The lowest proliferation was observed in
the Luminal subgroup.
We then applied the 14% cut-off point to WS, CNB and TMA.
Among hormone receptor positive cases, excluding Luminal B/
HER2+, the following figures for the frequency of cases having
high proliferation were 52% (WS), 41% (CNB) and 14% (TMA),
as illustrated in Figure 2. In the study by Cheang and colleagues,
the Luminal B category comprised 36% of the HR+/HER2
negative cases [3]. By applying this frequency to our series, the
following cut-off points for Ki67 would result in a similar size of
the Luminal B (HER2 negative) subgroup: 20% (WS), 15% (CNB)
and 8% (TMA).
We further applied the 14% cut-off point (St Gallen 2011) in the
Luminal subgroup (excluding Luminal B/HER2+) and found
classification agreement in 65% of the cases when comparing WS
and CNB (n= 125, paired cases) as illustrated in Table 4 (kappa-
value 0.29, P,0.001). Of note, 18 cases (14%) initially categorized
as luminal B on CNB were downgraded on WS, whereas 26 cases
(21%) categorized as luminal A on CNB were upgraded. We then
compared the results between WS and TMA (n=350, paired
cases) and found concordance in 59% of cases (kappa-value 0.23,
P,0.001). 143 cases (41%) categorized as luminal A on TMA
were upgraded on WS, whereas only 1 case showed the opposite
pattern.
Tumor cell proliferation and patient outcome
Univariate analyses displayed significant associations between
Ki67-WS and patient survival using a cut-off at the median
(Figure 3, see also table S3 in File S1). Further, significant
influence of Ki67-WS counts was shown for all cut-points
examined (10th–90th percentiles, Figure S4). Multivariate survival
analyses, after adjustment for basic prognostic indicators including
age, tumor size, histologic grade and lymph node status, showed
that Ki67, tumor size and nodal stage were independent
prognostic factors for breast cancer specific survival (Table 5).
Proliferation by Ki67-CS showed similar but weaker effects on
BCSS in univariate analysis (Table S4 in File S1). We further
performed survival analyses after excluding the 33 cases with
locally advanced disease; the results were similar (data not shown).
Table 3. Associations between Ki67 expression and histopathological features.
Ki67-WS (n=534) Ki67-CNB (n=154) Ki67-TMA (n=459)
Variables Median (%) P-valuea Median (%) P-valuea Median (%) P-valuea
Tumor diameter ,0.001 0.089 ,0.001
#2 cm 16.8 11.2 6.2
.2 cm 28.0 16.8 11.2
Histologic grade ,0.001 ,0.001 ,0.001
1 12.0 9.2 4.4
2 19.5 14.1 7.0
3 43.7 40.0 23.4
Nodal statusb 0.002 NS 0.002
Negative 16.8 11.9 6.2
Positive 23.3 14.4 8.7
ER ,0.001 ,0.001 ,0.001
Positive 16.6 11.0 6.0
Negative 42.8 40.0 19.0
PR ,0.001 0.005 ,0.001
Positive 16.8 11.1 6.0
Negative 26.2 19.3 12.0
HER2 ,0.001 0.088 ,0.001
Negative 16.8 11.7 6.0
Positive 32.4 18.4 15.2
NS, not significant.
aMann-Whitney or Kruskal-Wallis tests.
b5 cases (WS), 1 case (CNB) and 4 cases (TMA) with unknown lymph node status were excluded.
doi:10.1371/journal.pone.0112121.t003
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Univariate survival analysis of Ki67 in CNB sections showed all
examined cut-points above the 40th percentile to be prognostic.
Multivariate analyses were performed, adjusting for age, tumor
size, histologic grade and nodal status. In the final model, Ki67-
CNB and nodal status retained prognostic significance.
For Ki67 in TMA sections, univariate survival analyses demon-
strated all examined cut-points above the 10th percentile to be
prognostic. In multivariate analysis, including the variables age, tumor
size, histologic grade and nodal status, Ki67-TMA showed indepen-
dent prognostic impact in addition to tumor size and nodal status.
Finally, Ki67 on WS, CNB and TMA (paired cases, n = 137)
were included in a multivariate analysis. In this model, only Ki67-
WS demonstrated independent prognostic significance. (HR 1.06;
(1.02–1.10), P=0.006, Ki67 included as a continuous variable).
Survival by Ki67 in different molecular subgroups
We also performed subgroup analyses on the complete series
stratified by ER and HER2 status and based on Ki67-WS. In the
luminal category (including Luminal-HER2+; n= 462), univariate
survival analysis revealed a significant association between Ki67 and
BCSS (HR 1.03, 95% CI=1.02 to 1.04; P,0.001), also when using
two categories with a defined cut-point of 14%, (HR 2.9, 95%
CI=1.5 to 5.5; P=0.001; Figure 4). In multivariate analysis
including Ki67 and the basic prognostic variables tumor size,
histologic grade and lymph node status, Ki67 retained prognostic
significance (together with nodal status and tumor size). Further-
more, by excluding the HER2+ cases and focusing on HR+ breast
cancers (n=412), similar results were obtained (data not shown). In
contrast, univariate survival analysis revealed no significant associ-
ation between Ki67 and outcome within the HER2+/HR-
subgroup. By including the HER2+/HR+ cases, the analysis showed
prognostic impact of Ki67 (HR 1.027, 95% CI 1.002–1.053;
P=0.033). Finally, univariate analysis demonstrated no association
between Ki67 and survival in triple negative breast cancer.
Discussion
It is well documented that tumor cell proliferation by Ki67
expression is strongly associated with breast cancer prognosis [15].
After the suggestion of Ki67 as a predictive marker for adjuvant
chemotherapy, observer variation and methodological issues have
been increasingly discussed [8,16]. Some recommendations for
Ki67 assessment were presented in 2011, and the lack of
systematic comparisons of Ki67 expression levels between tissue
microarrays (TMA) and whole sections (WS) was noted [8]. As an
example, the Ki67 cut-off point of 14% recommended for
treatment decisions by the St Gallen 2011 guidelines was based
on data from a series of tissue microarrays combined with gene
expression analysis [3,7]. However, the clinical translation of these
findings has not been well documented.
Here, we found a significant difference in proliferation level
related to specimen type, with median Ki67 staining values of
18%, 13% and 7% for WS, CNB and TMA samples. These
differences might in part be explained by intra-tumor heteroge-
neity, which is seen both at the morphological and molecular levels
[17–25].
Studies based on CNB and TMA specimens are challenging as
the amount of tissue examined is reduced compared with WS
Figure 1. Box plots of tumor cell proliferation by Ki67 expression according to breast cancer molecular subgroups in different
specimen categories. Horizontal lines inside the boxes represent the median value; box limits indicate the 25th and 75th percentiles; whiskers
extend 1.5 times the interquartile range from the 25th and 75th percentiles.
doi:10.1371/journal.pone.0112121.g001
Figure 2. Frequency of cases in the Luminal/HER2- subgroup
showing high proliferation when applying a Ki67 cutoff-point
of 14% to different specimen categories. WS (n=415), CNB
(n=125), TMA (n= 350).
doi:10.1371/journal.pone.0112121.g002
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Table 4. Ki67 concordance between WS, CNB and TMA in the luminal subgroup.
WS Agreement Kappa P-value
LumA LumB
N (%) N (%)
CNB
LumA 48 (38) 26 (21) 65% 0.29 0.001
LumB 18 (14) 33 (26)
TMA
LumA 158 (45) 143 (41) 59% 0.23 ,0.001
LumB 1 (0.3) 48 (14)
doi:10.1371/journal.pone.0112121.t004
Figure 3. Breast cancer specific survival according to Ki67 expression. Survival curves (Kaplan-Meier) are shown for Ki67 expression on WS
(A); TMA (B) and CNB (C). Cut-off points at the median were applied for all specimen categories. The number of events and total number of patients in
each group are shown beside the description of each curve. Numbers at risk are presented below each curve.
doi:10.1371/journal.pone.0112121.g003
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samples. Heterogeneity might especially affect studies using the
hot-spot approach, since these areas are often small and might be
missed on CNB and TMA sections. Still, prior studies of
proliferation markers in breast tumors have shown good statistical
correlation between TMA and full sections for Ki67 [26–28], and
expected associations between Ki67 and clinico-pathologic and
molecular features have been reproduced [29]. Also, the use of
pre-surgical CNB has been validated for various biomarkers with
significant correlation between methods [30]. Good to excellent
agreement has been demonstrated for hormone receptors and
HER2 status, whereas histologic grade has shown only modest
concordance, mainly due to underestimation of mitotic count on
CNB specimens [31–35]. Some studies on Ki67 have shown good
concordance between CNB and WS tissues [36–39], whereas
others have found only fair to moderate agreement [25,40,41].
Notably, even in studies demonstrating a good statistical correla-
tion, there could be marked differences in scores on an individual
basis [36]. In our study, a significant proportion of the cases are
classified differently given a predetermined threshold and with
potential consequences for patient treatment. Importantly, we
found that 21% of Luminal A cases on CNB were upgraded to
Luminal B on WS specimens, similar to other findings [42].
The subdivision of ER-positive tumors into Luminal A and
Luminal B is based on the expression levels of proliferation-related
genes among HER2 negative cases. Studies have revealed that
proliferation levels are continuous, and sub-classification based on
certain cut-points is therefore likely to be arbitrary [43,44].
Although the 14% cut-off point to separate Luminal A from
Luminal B tumors was based on Ki67 expression in TMA samples
and established against gene expression profiles, this cut-point
showed only a modest sensitivity of 77% and a specificity of 78%
in that study [3]. In spite of this, the 14% threshold has been used
in research settings as well as in the St Gallen 2011 statement for
clinical implementation. Interestingly, the size of the Luminal B
subgroup has varied from 8% [45] to 66% [46] in published series.
In our study, the 14% cut-off point results in an overestimation of
the Luminal B subgroup based on WS specimens, whereas the
TMA approach appears to underestimate same group. In the
study by Cheang and colleagues, the Luminal B category
represents 36% of the HR+/HER2 negative cases [3]. We applied
Table 5. Multivariate survival analysis (Cox9 proportional hazards method) using different specimen categories.
Variables N HR 95% CI P-valuea
A. Whole sections (final model; n = 529)
Tumor diameter
#2 cm 404
.2 cm 125 2.3 1.4–3.7 0.001
Nodal status
Negative 387
Positive 142 3.3 2.0–5.3 ,0.001
Ki67 countb
Low, #18.3 265
High,.18.3 264 2.4 1.4–4.1 0.001
B. Core needle biopsies (final model; n = 153)
Nodal status
Negative 112
Positive 41 4.2 1.9–9.5 0.001
Ki67 countb
Low, #12.8 77
High,.12.8 76 2.8 1.1–6.7 0.024
C. TMAs (final model; n = 455)
Tumor diameter
#2 cm 346
.2 cm 109 2.0 1.2–3.5 0.009
Nodal status
Negative 335
Positive 120 3.5 2.0–6.0 ,0.001
Ki67 countb
Low, #7.0 236
High,.7.0 219 2.2 1.3–3.7 0.005
HR, Hazard ratio; CI, confidence interval.
Final models after initial inclusion of age, tumor diameter, histologic grade, nodal status and Ki67.
5 cases (WS), 1 case (CNB) and 4 cases (TMA) were excluded due to missing information on lymph node status.
aLikelihood ratio.
bCut-off point at the median.
doi:10.1371/journal.pone.0112121.t005
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this frequency to our series, and found that the following cut-off
points for Ki67 would result in a similar size of the Luminal B-
HER2 negative subgroup: 20% (WS), 15% (CNB) and 8% (TMA).
Thus, the importance of tissue-specific cut-off points must be
considered, for instance when using core needle biopsies and when
translating data from TMA-based research to a potential clinical
use.
For prognostic purposes, there is no consensus regarding
counting area or how many tumor cells should be scored [8].
Although a previous study showed that both the peripheral,
central and average Ki67 rates were associated with overall
survival [17], two recent studies have revealed that Ki67 has the
strongest prognostic impact when counted in hot-spot areas
[47,48]. Notably, using whole sections and hot-spot readings
corresponds to what is done for mitotic activity as part of histologic
grading. Since prognostic studies have indicated that disease
progression is best predicted by Ki67 counted in hot-spot areas, a
similar approach should probably be considered for predictive
purposes. This must be assessed in carefully designed studies.
Regarding methodology, our study has some limitations, since
pre-analytical and analytical variables can not be completely
standardized in such retrospective studies [8]. Delayed formalin
fixation may result in decreased expression of certain biomarkers
[49], although a study of Ki67 found no decrease in expression
after 180 minutes delay [50]. Of note, it has been shown that
prolonged formalin fixation may cause more extensive masking of
antigens, and that not all of this loss can be recovered by antigen
retrieval [51,52]. Further, the TMA technique carries some
drawbacks, such as sampling errors and loss of information due to
missing tissue cores. Notably, false negative results have been
reported for biomarkers studied on TMA sections [53], but it is not
known whether this is applicable to Ki67. Regarding ER and PR
expression, we used a threshold of 10% for molecular sub-
classification according to national guidelines at the time, as
compared to the 1% threshold recommended by the present St
Gallen guidelines.
In conclusion, tumor cell proliferation as estimated by Ki67 is
significantly dependent on specimen category, and our results
indicate that specimen-specific cut-off values should be established
and validated for clinical use. Furthermore, Ki67 is prognostic
over a wide range of cut-off points. For practical purposes, whole
sections should be preferred when available, in parallel to the
assessment of mitotic count as an integral part of histologic
grading. When using hot-spot readings on whole sections, a cut-off
point of 20% as a minimum for Ki67 seems to be appropriate at
least to predict disease progression. This is also in line with the
recent St Gallen 2013 statement [10]. The value of Ki67 as a
predictive marker needs to be further studied and validated.
Supporting Information
File S1 Supplementary tables. Table S1. Clinico-patholog-
ical features and associations with molecular subtypes of breast
cancer. Table S2. Ki67 assessed in hot-spots and cold-spots on WS
specimens and associations with histopathological variables. Table
S3. Univariate survival analysis according to histopathological
variables (Kaplan-Meier method). Table S4. Unadjusted Cox
proportional hazards analysis used to estimate the prognostic value
of Ki67 expression according to specimen category.
(PDF)
Figure S1 A. Ki67 expression scores across specimen category.
The median and inter-quartile range of Ki67 is shown according
to specimen type. B. Bland-Altman plot is shown for Ki67
expression on whole sections and core needle biopsies. Ki67
difference (WS-CNB) versus average of WS and CNB with 95%
limits of agreement (LOA). The mean difference was 2.8% (95%
LOA between -22 and 27; P=0.005). C. Bland-Altman plot is
shown for Ki67 expression on whole sections and TMA. Ki67
difference (WS-TMA) versus average of WS and TMA with 95%
LOA. The mean difference was 10% (95% LOA between -10 and
36; P,0.001).
(TIF)
Figure S2 Scatter plots with line of equality illustrating
the relationships between counts based on WS, CNB,
and TMA specimens.
(TIF)
Figure S3 Frequency of cases showing high prolifera-
tion when applying a Ki67 cut-off point of 14% to
different specimen categories, WS (n=534), CNB
(n=154), TMA (n=459).
(TIF)
Figure S4 Unadjusted Cox proportional hazards analy-
sis used to estimate the prognostic value of possible
Ki67 cut-off points. The hazard ratio (solid lines) including
95% CI (dashed lines) is shown in dependence of Ki67 cut-off
points based on percentiles, with separate plots for WS (A), TMA
(B), and CNB (C) specimens.
(TIF)
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Figure 4. Breast cancer prognosis by molecular subtype.
Survival curves (Kaplan-Meier) for breast carcinomas showing an
association between molecular subtype and breast cancer specific
survival. The Luminal B subgroup includes Luminal/HER2+ cases. For
each category, the number of events is given followed by the number
of patients.
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